SW · PRFN.SW
Kinarus Therapeutics Holding AG
- Sector
- Industrials · Airlines, Airports & Air Services
- Headquarters
- Lausanne 1006
- Website
- kinarus.com
Price · as of 2020-12-31
$0.04
Market cap 0
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $0.01 | -83.43% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2006 | $0.00 | $0.00 | |||
| 2007 | $0.00 | $63.32 | |||
| 2008 | $0.00 | $10.40 | |||
| 2009 | $0.08 | $4.36 | |||
| 2010 | $0.09 | $1.32 | |||
| 2011 | $0.06 | $0.00 | |||
| 2012 | $0.03 | $0.00 | |||
| 2013 | $0.01 | $0.04 | |||
| 2014 | $0.00 | $0.01 | |||
| 2015 | $0.00 | $0.24 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $0.00 | $0.01 |
AI valuation
Our deep-learning model estimates Kinarus Therapeutics Holding AG's (PRFN.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.04
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
$0.01
-83.43% upside
About Kinarus Therapeutics Holding AG
Perfect Holding SA, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 MAPK inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company is based in Lausanne, Switzerland.
- CEO
- Jean-Claude Roch
- Employees
- 15
- Beta
- 2.93
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.04) − 1 = — (DCF, example).